Drugs / XCEL-M-ALPHA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02033525 | Jan 2014 → May 2017 | — | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XCEL-M-ALPHA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02033525 ↗ |
| Modality | Cell therapy | “autologous ex vivo expanded mesenchymal stromal cells” NCT02033525 ↗ |
| Route | Other | “Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)” NCT02033525 ↗ |